COGR submitted comments to the FDA highlighting significant barriers that hinder cannabis research, namely limited access to diverse cannabis strains due to stringent federal regulations and unclear guidelines regarding cannabidiol (CBD) research. COGR urges the FDA to collaborate with relevant federal agencies to expand the number of authorized cannabis growers, clarify regulatory requirements for hemp-derived CBD products, and establish mechanisms such as stakeholder roundtables to address research obstacles. The letter also endorses recommendations to streamline bureaucratic processes and improve access, funding, and research quality to better inform regulatory decisions regarding cannabis and its derivatives.
This summary was generated with AI. Report Issue
Document
